These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18199501)

  • 21. Clinical benefits of a metabolic approach in the cardiac rehabilitation of patients with coronary artery disease.
    Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
    Am J Cardiol; 2006 Sep; 98(5A):25J-33J. PubMed ID: 16931203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel drugs for treating angina.
    Jones DA; Timmis A; Wragg A
    BMJ; 2013 Sep; 347():f4726. PubMed ID: 24018101
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina.
    Arnold SV; Kosiborod M; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Spertus JA
    JAMA Intern Med; 2014 Aug; 174(8):1403-5. PubMed ID: 24887304
    [No Abstract]   [Full Text] [Related]  

  • 24. [A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study].
    Rodríguez Padial L; Maicas Bellido C; Velázquez Martín M; Gil Polo B
    Rev Clin Esp; 2005 Feb; 205(2):57-62. PubMed ID: 15766476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of coronary artery disease and percutaneous intervention on the cardiac metabolism of nonesterified fatty acids and insulin: Implications of diabetes mellitus.
    Jaumdally RJ; Lip GY; Patel JV; MacFadyen RJ; Varma C
    J Intern Med; 2009 Jun; 265(6):689-97. PubMed ID: 19226374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolic treatment of coronary artery disease and heart failure.
    Di Napoli P
    Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
    [No Abstract]   [Full Text] [Related]  

  • 27. [Role of trimetazidine in the treatment of diabetic microangiopathy in ischaemic heart disease].
    Fi Z; Kovács G; Szentes V
    Orv Hetil; 2015 May; 156(19):765-8. PubMed ID: 26039915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of a superselective beta1-adrenoblocker nebivolol on the course of coronary heart disease and insulin resistance in patients with diabetes mellitus type 2 after coronary artery bypass grafting].
    Tepliakov AT; Kuznetsova AV; Lukinov AV; Levshin AV
    Ter Arkh; 2007; 79(12):38-43. PubMed ID: 18220029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
    Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of chronic stable angina pectoris.
    Rodríguez-Ospina L; Montano-Soto L
    Bol Asoc Med P R; 2008; 100(4):39-47. PubMed ID: 19400528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ischemic heart disease: metabolic approaches to management.
    Pauly DF; Pepine CJ
    Clin Cardiol; 2004 Aug; 27(8):439-41. PubMed ID: 15346837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modification of myocardial substrate use as a therapy for heart failure.
    Abozguia K; Clarke K; Lee L; Frenneaux M
    Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ; Mishra S
    Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.
    Kaliebe JW; Murdock DK
    WMJ; 2009 Oct; 108(7):373-5. PubMed ID: 19886587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular rehabilitation increase arterial compliance in type 2 diabetic patients with coronary artery disease.
    Mourot L; Boussuges A; Campo P; Maunier S; Debussche X; Blanc P
    Diabetes Res Clin Pract; 2009 May; 84(2):138-44. PubMed ID: 19264372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
    Tuunanen H; Engblom E; Naum A; Någren K; Scheinin M; Hesse B; Juhani Airaksinen KE; Nuutila P; Iozzo P; Ukkonen H; Opie LH; Knuuti J
    Circulation; 2008 Sep; 118(12):1250-8. PubMed ID: 18765391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proceedings: Clinical evaluation of perhexiline maleate in the treatment of chronic cardiac arrhythmias of patients with coronary heart disease.
    Sukerman M
    Postgrad Med J; 1973 Apr; 49():Suppl 3:46-52. PubMed ID: 4587032
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinicopathogenetic features of coronary heart disease combined with chronic obstructive pulmonary diseases and efficiency of therapy with trimetazidin].
    Kolomoets NM; Baksheev VI; Uvaĭsova KU
    Klin Med (Mosk); 2008; 86(6):38-43. PubMed ID: 18720710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New concepts in the therapy of diabetic cardiopathies].
    Pogátsa G
    Orv Hetil; 1997 Jun; 138(23):1491-4. PubMed ID: 9254364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.